HomeAI · summaries
Storia in 3 fonti
MapLight CEO on what investors missed in the biotech’s schizophrenia data
Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
MapLight dives despite positive data for schizophrenia drug
Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.
- ·
endpoints.news
MapLight’s schizophrenia drug disappoints once-daily hopes despite Phase 2 win
MapLight Therapeutics' $MPLT stock fell 60%+ after ML-007C-MA's once-daily regimen missed Phase 2 ZEPHYR trial's primary endpoint; twice-daily dose succeeded vs. placebo.
